Vertex Pharmaceuticals (NASDAQ: VRTX) has long been known for its expertise in treating cystic fibrosis (CF). The biotech is the market leader, bringing in billions of dollars in revenue and profit annually from its CF drugs. And that's likely to continue thanks to solid technology and a late-stage candidate that might even beat Vertex's current products in efficacy.